华人科学家俞君英《Stem Cell》文章

1997年，俞君英自北京 学生物系卒业后赴美国宾西法尼亚 学攻读生物博士学位，从事胚胎克隆范畴的研讨。2003年进入汤姆森试验室工作，并转向以人体皮肤细胞改组为干细胞的研讨。

本篇文章中，研讨人员重要对几种细胞的引诱多能性进行了周全的评价，用OP9分化体系判定了造血细胞系和内皮细胞系的iPS细胞的多能性。研讨中的iPS分离起源于人类的胚胎成纤维细胞，新生儿的成纤维细胞，成人的成纤维细胞，用这些细胞起源树立了7株iPS细胞系，引诱进程顶用POU5F1，SOX2，NANOG，和LIN28几个引诱因子。研讨者将这些iPS细胞与5株胚胎干细胞系（hESC，H1，H7，H9，H13和H14）的多能性进行了比较。

研讨成果发明，这些iPS细胞与人类胚胎干细胞一样具有类似的多能性，这些iPS细胞经引诱分化可表达造血细胞标志CD34CD43和内皮细胞标志CD31CD43。iPS细胞系与人类胚胎干细胞系的分化多能性很类似。它们都能分化成造血祖细胞和内皮祖细胞。

这些喜人的成果注解，iPS细胞有望用于人类的血液疾病和某些遗传性疾病的治疗。

原文检索：Hematopoietic and Endothelial Differentiation of Human Induced Pluripotent Stem Cells

Induced pluripotent stem cells (iPSCs) provide an unprecedented opportunity for modeling of human diseases in vitro, as well as for developing novel approaches for regenerative therapy based on immunologically compatible cells. In this study, we employed an OP9 differentiation system to characterize the hematopoietic and endothelial differentiation potential of seven human iPSC lines obtained from human fetal, neonatal, and adult fibroblasts through reprogramming with POU5F1, SOX2, NANOG, and LIN28 and compared it with the differentiation potential of five human embryonic stem cell lines (hESC, H1, H7, H9, H13, and H14). Similar to hESCs, all iPSCs generated CD34+CD43+ hematopoietic progenitors and CD31+CD43– endothelial cells in coculture with OP9. When cultured in semisolid media in the presence of hematopoietic growth factors, iPSC-derived primitive blood cells formed all types of hematopoietic colonies, including GEMM colony-forming cells. Human induced pluripotent cells (hiPSCs)-derived CD43+ cells could be separated into the following phenotypically defined subsets of primitive hematopoietic cells: CD43+CD235a+CD41a± (erythro-megakaryopoietic), lin–CD34+CD43+CD45– (multipotent), and lin–CD34+CD43+CD45+ (myeloid-skewed) cells. Although we observed some variations in the efficiency of hematopoietic differentiation between different hiPSCs, the pattern of differentiation was very similar in all seven tested lines obtained through reprogramming of human fetal, neonatal,oradult fibroblasts with threeorfour genes. Although several issues remain to be resolved before iPSC-derived blood cells can be administered to humans for therapeutic purposes, patient-specific iPSCs can already be used for characterization of mechanisms of blood diseases and for identification of molecules that can correct affected genetic networks. STEM CELLS 2009;27:559–567